The duration of flare-free maintenance was the time from randomization to the last Investigator's Static Global Assessment (ISGA) and was right censored, if an intercurrent event (eg, death, dropout, loss to follow up, or end of study) occurred before the first flare. When a flare occurred first, the duration of flare free maintenance was the time from randomization to the first flare and was not censored. Duration of flare free maintenance was estimated using the Kaplan-Meier method.

Evaluable-DB (Eval-DB) population included all randomized participants with success in ISGA (i.e., achieving a score of clear [0] or almost clear [1] with a >=2 grade improvement from the run-in baseline) and Eczema Area Severity Index score (EASI50) criteria as responders at randomization and received at least 1 dose of study intervention in the DB period.

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started on or after the treatment period start date and before end of study (at least 28 days after last dose of study intervention).

Safety population comprised of all participants who received at least 1 dose of study intervention during the study.

Flare - free days was the sum of the duration of flare-free maintenance during the DB maintenance period for each participant.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period.

Flare was defined as an ISGA score of >=2. The ISGA is a 5-point scale (range 0 to 4), reflecting a global assessment of AD severity based on erythema, induration/papulation, and oozing/crusting. ISGA score of 2: mild (faint pink erythema with mild induration/papulation and no oozing/crusting) 3: moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting) and 4: severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting).

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period.

Duration of pruritus response maintenance=time from randomization to loss of pruritus response or first flare onset(ISGA>=2) during 52-week DB period evaluated among pruritus responders at randomization. Responders=participants with success in ISGA and EASI50 criteria. Pruritus response maintenance=maintenance of >=50% improvement in pruritus from baseline obtained at randomization. If event (e.g., death, first flare[ISGA >=2], lost to follow up or end of study) occurred before loss of pruritus response for first flare-free period, duration of pruritus response maintenance was time from randomization to last assessment and was censored. Here,pruritus response maintenance duration was presented for participants aged >=12 years with OL baseline PP NRS >=3, >=4 and >=3, >=4 points reduction from OL baseline to randomization in PP NRS. PP NRS: Participants were asked to rate their itch at worst moment during previous 24 hours on a scale of 0 to 10; 0=no itch and 10=worst itch imaginable".

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, '"Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and "Number Analyzed'' signifies participants evaluable for specified rows.

Duration of pruritus response maintenance=time from randomization to loss of pruritus response or first flare onset (ISGA>=2) during 52-week DB period. Evaluated among pruritus responders at randomization. Responders were defined as participants with success in ISGA and EASI50 criteria. Pruritus response maintenance=maintenance of >=50% improvement in pruritus from baseline that was obtained at randomization. If an event (e.g., death, first flare [ISGA >=2], lost to follow up, or end of study) occurred before loss of pruritus response for first flare-free period, duration of maintenance of pruritus response was time from randomization to last assessment and was censored. Here, pruritus response maintenance duration was presented for participants aged 6 to <12 years with baseline PRIS >=2 and >=2 points reduction from baseline to randomization in PRIS. PRIS: a 5-point scale (range: 0=no itch to 4=worst itch imaginable) and was completed by participants.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure.

Duration of pruritus response maintenance=time from randomization to loss of pruritus response or first flare onset(ISGA>=2)during52-weekDB period. Evaluated among pruritus responders (success in ISGA, EASI 50) at randomization. Pruritus response maintenance=maintenance of >=50% improvement in pruritus from baseline obtained at randomization. If event(e.g., death, first flare[ISGA >=2], lost to follow up, or end of study) occurred before loss of pruritus response for first flare-free period, duration of maintenance of pruritus response was time from randomization to last assessment and was censored. Here, pruritus response maintenance duration was presented for participants aged 3 to <6 months with OL baseline ORIS>=3 or >=4 and >=3 or >=4 points reduction from OL baseline to randomization in ORIS. Caregivers were asked to rate observation of their child's itch(scratching, rubbing) at worst moment during previous 24 hours on a scale of 0 to 10;0=no itch,10=worst itch imaginable.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''number of participants analyzed'' signifies participants evaluable at specified rows.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema [E], induration/papulation [I], excoriation [Ex], lichenification [L]) and % body surface area (BSA) affected. Each of clinical signs scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin], lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) according to %BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD. EASI response maintenance = score that does not lose more than 50% of achieved reduction from Day1/Baseline run-in EASI score.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period.

Duration of DLQI maintenance=time from randomization to loss of DLQI response during 52-week DB period for responders at randomization. If event(e.g., death, first flare[ISGA >=2], lost to follow up or end of study) occurred before loss of DLQI response, duration of maintenance of DLQI response=time from randomization to last assessment and censored. Responders=participants with success in ISGA,EASI50 criteria. DLQI response maintenance=response that does not lose more than minimal clinical important difference. DLQI =10-item questionnaire, measured impact of skin disease in participants aged >=16 years. Children's DLQI (CDLQI): participants aged 4 to15 years. Each question in DLQI and CDLQI evaluated on 4-point scale (range 0=not at all to 3=very much). Scores from10 items were added for DLQI/CDLQI total score, range:0 (not at all) to 30 (very much). Higher scores=more impact on quality of life of participants/children.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''number of participants analyzed'' signifies participants evaluable for specified rows.

POEM was a 7-item participant reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item was scored as: no days=0, 1-2 days=1, 3-4 days=2, 5-6 days=3 and every day=4. The total score ranged from 0 to 28, where higher score indicated greater severity. POEM response maintenance was defined as the response that does not lose more than minimal clinical important difference. Duration of POEM maintenance was time from randomization to loss of POEM response during 52-week DB period for responders at randomization. Responders were defined as participants with success in ISGA and EASI50 criteria. If an event (e.g., death, first flare [ISGA >=2], lost to follow up, or end of study) occurred before loss of POEM response, duration of maintenance of POEM response was time from randomization to last assessment and was censored. Proxy POEM was used for participants aged 3 months to <12 years.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable for specified rows.

ISGA:5- point global assessment scale of AD severity, used to characterize overall disease severity across all treatable AD lesions (excluding the scalp). Score ranged from 0 to 4: where 0= clear(minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicate greater severity of AD. First flare period was the time from the onset of flare (ISGA>=2) during DB maintenance period where the participant was switched to receive open-label crisaborole ointment 2%, BID for up to 12 weeks until resolution of flares.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema[E], induration/papulation[I], excoriation[Ex], lichenification[L]) and % body surface area(BSA) affected.Each of clinical signs scored separately for each of 4 body regions (head and neck[h], upper limbs[u], trunk[t] [including axillae and groin], lower limbs[l] [including buttocks]) on 4-point scale: 0= absent; 1=mild; 2= moderate; 3= severe.EASI area score(A) according to %BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD.First flare period=time from onset of flare(ISGA>=2) during DB maintenance period where participant was switched to receive open-label crisaborole ointment 2%,BID for up to 12 weeks until resolution of flares.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number of Participants Analyzed'' signifies participants evaluable at specified time points.

Duration of flare period was average duration calculated from sum of durations divided by number of flares for each participant.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema [E], induration/papulation [I], excoriation [Ex], lichenification [L]) and % body surface area (BSA) affected. Each of clinical signs scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin], lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) according to %BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD.

Evaluable-OL (Eval-OL) population included all participants that received at least 1 dose of study intervention in the OL period.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema [E], induration/papulation [I], excoriation [Ex], lichenification [L]) and % body surface area (BSA) affected. Each of clinical signs scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin], lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) according to %BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema [E], induration/papulation [I], excoriation [Ex], lichenification [L]) and % body surface area (BSA) affected. Each of clinical signs scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin], lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) according to % BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EASI assessed severity of AD, based on severity of lesion clinical signs (erythema [E], induration/papulation [I], excoriation [Ex], lichenification [L]) and % body surface area (BSA) affected. Each of clinical signs scored separately for each of 4 body regions (head and neck [h], upper limbs [u], trunk [t] [including axillae and groin], lower limbs [l] [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score (A) according to %BSA with AD: 0 (0%), 1(>0 to <10%), 2(10 to <30%), 3(30 to <50%), 4(50 to <70%), 5(70 to <90%), 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh + Ih + Exh + Lh) + 0.2*Au*(Eu + Iu + ExU + Lu) + 0.3*At*(Et +It + Ext + Lt) + 0.4*Al*(El + Il + Exl + Ll). Total EASI score ranged from 0.0 to 72.0, higher score = greater severity of AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Number Analyzed'' signifies participants evaluable at specified time points.

ISGA is a 5- point global assessment scale, used to characterize overall disease severity across all treatable AD lesions (excluding the scalp). Score ranged from 0 to 4: where 0= clear(minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicate greater severity of AD.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period.

ISGA is a 5- point global assessment scale, used to characterize overall disease severity across all treatable AD lesions (excluding the scalp). Score ranged from 0 to 4: where 0= clear(minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicate greater severity of AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Number Analyzed'' signifies participants evaluable at specified time points.

ISGA is a 5- point global assessment scale, used to characterize overall disease severity across all treatable AD lesions (excluding the scalp). Score ranged from 0 to 4: where 0= clear(minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1= almost clear (trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2= mild (faint pink erythema with mild induration/papulation and no oozing/crusting), 3= moderate (pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4= severe (deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicate greater severity of AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Number Analyzed'' signifies participants evaluable at specified time points.

ISGA:5-point global assessment scale, used to characterize overall disease severity across all treatable AD lesions (excluding scalp). Score ranged:0 to 4,where 0=clear(minor residual hypo/hyperpigmentation; no erythema or induration/papulation; no oozing/crusting), 1=almost clear(trace faint pink erythema, with barely perceptible induration/papulation and no oozing/crusting), 2=mild(faint pink erythema with mild induration/papulation and no oozing/crusting), 3=moderate(pink-red erythema with moderate induration/papulation with or without oozing/crusting), 4=severe(deep or bright red erythema with severe induration/papulation and with oozing/crusting). Higher scores indicate greater severity of AD. The period for which OL crisaborole 2% ointment BID was initiated for treatment of flare developed during DB maintenance until resumption of DB treatment was defined as flare treatment period.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The extent (%) to which a body region was involved with AD was determined using handprint method. Four body regions evaluated: head and neck (hn), upper limbs (ul), trunk (tr) (including axillae) and lower limbs (ll) (including buttocks). Total number of handprints=10 for hn, 20 for ul, 30 for tr, 40 for ll in participants aged >=8 years; 20 for hn, 20 for ul, 30 for tr, 30 for ll in participants aged 3 months to 7 years. Surface area of body region equivalent to 1 handprint: 10% for hn, 5% for ul, 3.33% for tr, 2.5% for ll in participants aged >=8 years; 5% for hn, 5% for ul, 3.33% for tr, 3.33% for ll in participants aged 3 months to 7 years. % BSA for a body region= total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual=sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater extent of BSA involvement with AD.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period.

The extent (%) to which a body region was involved with AD was determined using handprint method. Four body regions evaluated: head and neck (hn), upper limbs (ul), trunk (tr) (including axillae) and lower limbs (ll) (including buttocks). Total number of handprints=10 for hn, 20 for ul, 30 for tr, 40 for ll in participants aged >=8 years; 20 for hn, 20 for ul, 30 for tr, 30 for ll in participants aged 3 months to 7 years. Surface area of body region equivalent to 1 handprint: 10% for hn, 5% for ul, 3.33% for tr, 2.5% for ll in participants aged >=8 years; 5% for hn, 5% for ul, 3.33% for tr, 3.33% for ll in participants aged 3 months to 7 years. % BSA for a body region= total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual=sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater extent of BSA involvement with AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Number Analyzed'' signifies participants evaluable at specified time points.

The extent (%) to which a body region was involved with AD was determined using handprint method. Four body regions evaluated: head and neck (hn), upper limbs (ul), trunk (tr) (including axillae) and lower limbs (ll) (including buttocks). Total number of handprints=10 for hn, 20 for ul, 30 for tr, 40 for ll in participants aged >=8 years; 20 for hn, 20 for ul, 30 for tr, 30 for ll in participants aged 3 months to 7 years. Surface area of body region equivalent to 1 handprint: 10% for hn, 5% for ul, 3.33% for tr, 2.5% for ll in participants aged >=8 years; 5% for hn, 5% for ul, 3.33% for tr, 3.33% for ll in participants aged 3 months to 7 years. % BSA for a body region= total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual=sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater extent of BSA involvement with AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Number Analyzed'' signifies participants evaluable at specified time points.

The extent (%) to which a body region was involved with AD was determined using handprint method. Four body regions evaluated: head and neck (hn), upper limbs (ul), trunk (tr) (including axillae) and lower limbs (ll) (including buttocks). Total number of handprints=10 for hn, 20 for ul, 30 for tr, 40 for ll in participants aged >=8 years; 20 for hn, 20 for ul, 30 for tr, 30 for ll in participants aged 3 months to 7 years. Surface area of body region equivalent to 1 handprint: 10% for hn, 5% for ul, 3.33% for tr, 2.5% for ll in participants aged >=8 years; 5% for hn, 5% for ul, 3.33% for tr, 3.33% for ll in participants aged 3 months to 7 years. % BSA for a body region= total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual=sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater extent of BSA involvement with AD.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The investigators were required to draw the skin areas affected by AD for each participant in a body map and the most commonly affected BSA was documented.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The severity and frequency of itch (pruritus) during the night due to AD was assessed using a horizontal scale. Participants 12 years of age or older were asked to assess their worst itching and frequency of itching due to AD during their most recent night's sleep on a scale of 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Scale range of Frequency of night time itch was 0 to 10, where 0=no and 10=the most frequency imaginable. Higher score indicated higher frequency.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The severity and frequency of itch (pruritus) during the night due to AD was assessed using a horizontal scale. Participants 12 years of age or older were asked to assess their worst itching and frequency of itching due to AD during their most recent night's sleep on a scale of 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Scale range of Frequency of night time itch was 0 to 10, where 0=no and 10=the most frequency imaginable. Higher score indicated higher frequency.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The severity and frequency of itch (pruritus) during the night due to AD was assessed using a horizontal scale. Participants 12 years of age or older were asked to assess their worst itching and frequency of itching due to AD during their most recent night's sleep on a scale of 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Scale range of Frequency of night time itch was 0 to 10, where 0=no and 10=the most frequency imaginable. Higher score indicated higher frequency.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The severity and frequency of itch (pruritus) during the night due to AD was assessed using a horizontal scale. Participants 12 years of age or older were asked to assess their worst itching and frequency of itching due to AD during their most recent night's sleep on a scale of 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Scale range of Frequency of night time itch was 0 to 10, where 0=no and 10=the most frequency imaginable. Higher score indicated higher frequency.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Participants 12 years of age or older were asked to assess their worst skin pain due to AD at the analysis time, with the question: 'AD skin pain right now' using the skin pain numerical rating scale (NRS). Skin pain NRS was a 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Higher scores indicated worse pain.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Participants 12 years of age or older were asked to assess their worst skin pain due to AD at the analysis time, with the question: 'AD skin pain right now' using the skin pain numerical rating scale (NRS). Skin pain NRS was a 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Higher scores indicated worse pain.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Participants 12 years of age or older were asked to assess their worst skin pain due to AD at the analysis time, with the question: 'AD skin pain right now' using the skin pain numerical rating scale (NRS). Skin pain NRS was a 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Higher scores indicated worse pain.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Participants 12 years of age or older were asked to assess their worst skin pain due to AD at the analysis time, with the question: 'AD skin pain right now' using the skin pain NRS. Skin pain NRS was a 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Higher scores indicated worse pain.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Patient/Observer Global Impression of Severity (PGIS/OGIS) is a single item participant or observer rated measure of the participant's AD condition severity at a given point in time using a 7-point rating scale, which ranges from 1 to 7, where 1=not present to 7=extremely severe. The PGIS was completed by all participants >=12 years of age and OGIS was completed by the observer for participants 3 months-<12 years of age.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIS/OGIS is a single item participant or observer rated measure of the participant's AD condition severity at a given point in time using a 7-point rating scale, which ranges from 1 to 7, where 1=not present to 7=extremely severe. The PGIS was completed by all participants >=12 years of age and OGIS was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIS/OGIS is a single item participant or observer rated measure of the participant's AD condition severity at a given point in time using a 7-point rating scale, which ranges from 1 to 7, where 1=not present to 7=extremely severe. The PGIS was completed by all participants >=12 years of age and OGIS was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIS/OGIS is a single item participant or observer rated measure of the participant's AD condition severity at a given point in time using a 7-point rating scale, which ranges from 1 to 7, where 1=not present to 7=extremely severe. The PGIS was completed by all participants >=12 years of age and OGIS was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

Patient/Observer Global Impression of Change (PGIC/OGIC) is a single item instrument using 7-point rating scale and was used to determine global improvement at a given point in time since the start of study drug. The scores ranged from 1=very much improved to 7=very much worse. The PGIC was completed by all participants >=12 years of age and OGIC was completed by the observer for participants 3 months-<12 years of age.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIC/OGIC is a single item instrument using 7-point rating scale and was used to determine global improvement at a given point in time since the start of study drug. The scores ranged from 1=very much improved to 7=very much worse. The PGIC was completed by all participants >=12 years of age and OGIC was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIC/OGIC is a single item instrument using 7-point rating scale and was used to determine global improvement at a given point in time since the start of study drug. The scores ranged from 1=very much improved to 7=very much worse. The PGIC was completed by all participants >=12 years of age and OGIC was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

PGIC/OGIC is a single item instrument using 7-point rating scale and was used to determine global improvement at a given point in time since the start of study drug. The scores ranged from 1=very much improved to 7=very much worse. The PGIC was completed by all participants >=12 years of age and OGIC was completed by the observer for participants 3 months-<12 years of age.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

The Medical Outcomes Study (MOS) Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II) and a single item assessing quantity of sleep. Quantity of sleep scores ranged from 0 to 24 (number of hours slept) and Optimal Sleep score ranged from 0 (no) to 1(yes) based on whether the participant slept for 7-8 hours per night, All other subscales including sleep problems index 1 and 2:were scored on a range of 0 to 100 where, higher scores=greater impairment. Observed scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II) and a single item assessing quantity of sleep. Quantity of sleep scores ranged from 0 to 24 (number of hours slept) and Optimal Sleep score ranged from 0 (no) to 1(yes) based on whether the participant slept for 7-8 hours per night, All other subscales including sleep problems index 1 and 2:were scored on a range of 0 to 100 where, higher scores=greater impairment. Observed scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II) and a single item assessing quantity of sleep. Quantity of sleep scores ranged from 0 to 24 (number of hours slept) and Optimal Sleep score ranged from 0 (no) to 1(yes) based on whether the participant slept for 7-8 hours per night, All other subscales including sleep problems index 1 and 2:were scored on a range of 0 to 100 where, higher scores=greater impairment. Observed scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II) and a single item assessing quantity of sleep. Quantity of sleep scores ranged from 0 to 24 (number of hours slept) and Optimal Sleep score ranged from 0 (no) to 1(yes) based on whether the participant slept for 7-8 hours per night, All other subscales including sleep problems index 1 and 2:were scored on a range of 0 to 100 where, higher scores=greater impairment. Observed scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-5L: standardized participant completed questionnaire consisted of 2 components: a health state profile/a single utility index value and an optional VAS. EQ-5D health state profile/a single utility index value had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. US value sets (with all possible health states) was used for adults in the study and total scores ranged from 1 to -0.109. Higher (positive) scores = better health state.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y: child-friendly version of EQ-5D questionnaire related to health status. Health state profile assessed health in 5 dimensions (mobility; looking after myself; doing usual activities; having pain or discomfort; feeling worried, sad or unhappy) used to obtain an index score, each of which had three levels of response (no problems/no pain/not worried, some problems/some pain/a bit worried, a lot of problems/a lot of pain/very worried). Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where,-0.109= the worst health status, 1= full health. Higher the score the better the health status. A positive change from baseline indicated improvement in health status.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y:child-friendly version of EQ-5D questionnaire related to health status.Health state profile assessed health in 5 dimensions(Mobility;Looking After Myself;Doing Usual Activities;Having Pain or Discomfort;Feeling Worried,Sad or Unhappy)used to obtain index score,each of which had three levels of response(no problems/no pain/not worried,some problems/some pain/a bit worried,a lot of problems/a lot of pain/very worried).Participants indicated health state by choosing appropriate level from each dimension.5-digit health states obtained for each dimension were converted into single median index value using index value calculator,recommended by EuroQoL group.Health state index score calculated from individual health profiles using USA scoring algorithm. Scores ranged from -0.109 to 1,where, -0.109=worst health status, 1=full health. Higher score=better health status.Positive change from baseline indicated improvement in health status.Proxy version filled by care-giver of participant

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure.

EQ-5D-5L VAS was used to record participant's rating for current health-related quality of life state on vertical VAS (0-100);0=worst imaginable health state;100=best imaginable health state.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y VAS was used to record participant's rating for his/her current health-related quality of life state on vertical VAS (0-100);0 = worst imaginable health state and 100 = best imaginable health state.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y proxy VAS assessed the caregiver's impression of participants health state on a vertical VAS (range: 0 to 100), where, 0 (the worst imaginable health) to 100 (the best imaginable health).

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure.

EQ-5D-5L: standardized participant completed questionnaire consisted of 2 components: a health state profile/a single utility index value and an optional VAS. EQ-5D health state profile/a single utility index value had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQoL. US value sets (with all possible health states) was used for adults in the study and total scores ranged from 1 to -0.109. Higher (positive) scores = better health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y: child-friendly version of EQ-5D questionnaire related to health status. Health state profile assessed health in 5 dimensions (mobility; looking after myself; doing usual activities; having pain or discomfort; feeling worried, sad or unhappy) used to obtain an index score, each of which had three levels of response (no problems/no pain/not worried, some problems/some pain/a bit worried, a lot of problems/a lot of pain/very worried). Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where,-0.109= the worst health status, 1= full health. Higher the score the better the health status. A positive change from baseline indicated improvement in health status.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y:child-friendly version of EQ-5D questionnaire related to health status.Health state profile assessed health in 5 dimensions(Mobility;Looking After Myself;Doing Usual Activities;Having Pain or Discomfort;Feeling Worried,Sad or Unhappy)used to obtain index score,each of which had three levels of response(no problems/no pain/not worried,some problems/some pain/a bit worried,a lot of problems/a lot of pain/very worried).Participants indicated health state by choosing appropriate level from each dimension.5-digit health states obtained for each dimension were converted into single median index value using index value calculator,recommended by EuroQoL group.Health state index score calculated from individual health profiles using USA scoring algorithm. Scores ranged from -0.109 to 1,where, -0.109=worst health status, 1=full health. Higher score=better health status.Positive change from baseline indicated improvement in health status.Proxy version filled by care-giver of participant.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-5L VAS to record participant's rating for current health-related quality of life state on vertical VAS (0-100);0=worst imaginable health state;100=best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y VAS was a child-friendly version of EQ-5D questionnaire related to health status used to record participant's rating for his/her current health-related quality of life state on vertical VAS (0-100);0 = worst imaginable health state and 100 = best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y proxy VAS assessed the caregiver's impression of participants health state on a vertical VAS (range: 0 to 100), where, 0 (the worst imaginable health) to 100 (the best imaginable health).

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-5L: standardized participant completed questionnaire consisted of 2 components: a health state profile/a single utility index value and an optional VAS. EQ-5D health state profile/a single utility index value had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. US value sets (with all possible health states) was used for adults in the study and total scores ranged from 1 to -0.109. Higher (positive) scores = better health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y: child-friendly version of EQ-5D questionnaire related to health status. Health state profile assessed health in 5 dimensions (mobility; looking after myself; doing usual activities; having pain or discomfort; feeling worried, sad or unhappy) used to obtain an index score, each of which had three levels of response (no problems/no pain/not worried, some problems/some pain/a bit worried, a lot of problems/a lot of pain/very worried). Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where,-0.109= the worst health status, 1= full health. Higher the score the better the health status. A positive change from baseline indicated improvement in health status.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y:child-friendly version of EQ-5D questionnaire related to health status.Health state profile assessed health in 5 dimensions(Mobility;Looking After Myself;Doing Usual Activities;Having Pain or Discomfort;Feeling Worried,Sad or Unhappy)used to obtain index score,each of which had three levels of response(no problems/no pain/not worried,some problems/some pain/a bit worried,a lot of problems/a lot of pain/very worried).Participants indicated health state by choosing appropriate level from each dimension.5-digit health states obtained for each dimension were converted into single median index value using index value calculator,recommended by EuroQoL group.Health state index score calculated from individual health profiles using USA scoring algorithm. Scores ranged from -0.109 to 1,where, -0.109=worst health status, 1=full health. Higher score=better health status.Positive change from baseline indicated improvement in health status.Proxy version filled by care-giver of participant.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-5L VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y VAS was a child-friendly version of EQ-5D questionnaire related to health status used to record participant's rating for his/her current health-related quality of life state on vertical VAS (0-100);0 = worst imaginable health state and 100 = best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y proxy VAS assessed the caregiver's impression of participants health state on a vertical VAS (range: 0 to 100), where, 0 (the worst imaginable health) to 100 (the best imaginable health).

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y: child-friendly version of EQ-5D questionnaire related to health status. Health state profile assessed health in 5 dimensions (mobility; looking after myself; doing usual activities; having pain or discomfort; feeling worried, sad or unhappy) used to obtain an index score, each of which had three levels of response (no problems/no pain/not worried, some problems/some pain/a bit worried, a lot of problems/a lot of pain/very worried). Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where,-0.109= the worst health status, 1= full health. Higher the score the better the health status. A positive change from baseline indicated improvement in health status.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y: child-friendly version of EQ-5D questionnaire related to health status. Health state profile assessed health in 5 dimensions (mobility; looking after myself; doing usual activities; having pain or discomfort; feeling worried, sad or unhappy) used to obtain an index score, each of which had three levels of response (no problems/no pain/not worried, some problems/some pain/a bit worried, a lot of problems/a lot of pain/very worried). Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where,-0.109= the worst health status, 1= full health. Higher the score the better the health status. A positive change from baseline indicated improvement in health status.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-Y:child-friendly version of EQ-5D questionnaire related to health status.Health state profile assessed health in 5 dimensions(Mobility;Looking After Myself;Doing Usual Activities;Having Pain or Discomfort;Feeling Worried,Sad or Unhappy)used to obtain index score,each of which had three levels of response(no problems/no pain/not worried,some problems/some pain/a bit worried,a lot of problems/a lot of pain/very worried).Participants indicated health state by choosing appropriate level from each dimension.5-digit health states obtained for each dimension were converted into single median index value using index value calculator,recommended by EuroQoL group.Health state index score calculated from individual health profiles using USA scoring algorithm. Scores ranged from -0.109 to 1,where, -0.109=worst health status, 1=full health. Higher score=better health status.Positive change from baseline indicated improvement in health status.Proxy version filled by care-giver of participant.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D-5L VAS was used to record participant's rating for current health-related quality of life state on vertical VAS (0-100);0=worst imaginable health state;100=best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y VAS was a child-friendly version of EQ-5D questionnaire related to health status used to record participant's rating for his/her current health-related quality of life state on vertical VAS (0-100);0 = worst imaginable health state and 100 = best imaginable health state.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

EQ-5D Y proxy VAS assessed the caregiver's impression of participants health state on a vertical VAS (range: 0 to 100), where, 0 (the worst imaginable health) to 100 (the best imaginable health).

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI plus CIQ was a 10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1= currently employed; Q2= work hours missed due to health problems; Q3= work hours missed due to other reasons; Q4= hours actually worked; Q5= degree health affected productivity while working (0-10 scale, higher scores = less productivity); Q6= classes attended in academic setting or not; Q7= class hours missed due to health problems; Q8= class hours actually attended; Q9= degree health affected productivity while attending (0-10 scale, high scores= less productivity); Q10= degree health affected productivity in regular daily activities (0-10 scale, higher scores = less productivity). Percent work time missed was calculated as: Q2*100/(Q2+Q4) and score ranged from 0-100%, higher scores = greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were:Q1= currently employed;Q2= work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4= hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores=less productivity);Q6=classes attended in academic setting or not;Q7= class hours missed due to health problems; Q8= class hours actually attended; Q9= degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10= degree health affected productivity in regular daily activities (0-10 scale, high scores=less productivity). Percent impairment while working due to health problem was calculated as: 100*Q5/10 and score ranged from 0-100%,higher scores =greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days.Questions:Q1=currently employed;Q2=work hours missed due to health problems;Q3=work hours missed due to other reasons;Q4=hours actually worked;Q5=degree health affected productivity while working(0-10 scale, high scores=less productivity);Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems;Q8=class hours actually attended;Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity);Q10=degree health affected productivity: regular daily activities (0-10 scale, high scores =less productivity). Percent overall impairment while working due to health problem calculated as:100*{Q2/(Q2+Q4)+[(1- Q2/(Q2+Q4))×(Q5/10)]},score ranged:0-100%,high numbers=greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity).Percent class time missed due to health problem calculated as: Q7*100/(Q7+Q8) and score ranged from 0-100% where higher numbers=greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores =less productivity). Percent impairment while in class was calculated as: 100*Q9/10 and score ranged from 0-100% where higher numbers indicate greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past7days.Questions:Q1=currently employed;Q2=work hours missed due to health problems;Q3=work hours missed due to other reasons;Q4=hours actually worked;Q5=degree health affected productivity while working (0-10 scale, high scores=less productivity);Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems;Q8=class hours actually attended;Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity);Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity).Percent overall class impairment due to health problem calculated as: 100*{Q7/(Q7+Q8)+[(1- Q7/(Q7+Q8))×(Q9/10)]},score range:0-100%,higher numbers=greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions:Q1=currently employed;Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent activity impairment due to health problem calculated as: 100*Q10/10, score ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons;Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores=less productivity);Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems;Q8=class hours actually attended;Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity);Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores=less productivity). Percent work time missed due to health problem calculated as: Q2*100/(Q2+Q4) and score ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions:Q1=currently employed; Q2=hours missed due to health problems; Q3=hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=hours missed due to health problems; Q8=hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent impairment while working due to health problem calculated as: 100*Q5/10 score ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed;Q2=work hours missed due to health problems;Q3=work hours missed due to other reasons;Q4=hours actually worked;Q5=degree health affected productivity while working(0-10 scale, high scores=less productivity);Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems;Q8=class hours actually attended;Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity);Q10=degree health affected productivity: regular daily activities(0-10 scale, high scores =less productivity). Percent overall impairment while working due to health problem calculated as:100*{Q2/(Q2+Q4)+[(1- Q2/(Q2+Q4))×(Q5/10)]}, score ranged: 0-100%, high numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working(0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent class time missed due to health problem calculated as: Q7*100/(Q7+Q8) and score ranged from 0-100% where higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores =less productivity). Percent impairment while in class was calculated as: 100*Q9/10 and score ranged from 0-100% where higher numbers indicate greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores =less productivity). Percent overall class impairment due to health problem calculated as: 100*{Q7/(Q7+Q8)+[(1- Q7/(Q7+Q8))×(Q9/10)]}, score range:0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores=less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores= less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent activity impairment due to health problem calculated as: 100*Q10/10, score ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems;Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5= degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent work time missed due to health problem calculated as: Q2*100/(Q2+Q4) and score ranged from 0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=hours missed due to health problems; Q3=hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=hours missed due to health problems; Q8=hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent impairment while working due to health problem calculated as: 100*Q5/10 score ranged from 0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity: regular daily activities(0-10 scale, high scores =less productivity). Percent overall impairment while working due to health problem calculated as:100*{Q2/(Q2+Q4)+[(1- Q2/(Q2+Q4))×(Q5/10)]}, score ranged:0-100%, high numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working(0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent class time missed due to health problem calculated as: Q7*100/(Q7+Q8) and score ranged from 0-100% where higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent impairment while in class was calculated as: 100*Q9/10 and score ranged from 0-100% where higher numbers indicate greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores =less productivity). Percent overall class impairment due to health problem calculated as: 100*{Q7/(Q7+Q8)+[(1- Q7/(Q7+Q8))×(Q9/10)]}, score range:0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent activity impairment due to health problem calculated as: 100*Q10/10, score ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores=less productivity). Percent work time missed due to health problem calculated as: Q2*100/(Q2+Q4) and score ranged from 0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=hours missed due to health problems; Q3=hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=hours missed due to health problems; Q8=hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities (0-10 scale, high scores =less productivity). Percent impairment while working due to health problem calculated as: 100*Q5/10 score ranged from 0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ: 10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working(0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent overall impairment while working due to health problem calculated as:100*{Q2/(Q2+Q4)+[(1- Q2/(Q2+Q4))×(Q5/10)]}, score ranged:0-100%, high numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent class time missed due to health problem calculated as: Q7*100/(Q7+Q8) and score ranged from 0-100% where higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions:Q1=currently employed;Q2=work hours missed due to health problems;Q3=work hours missed due to other reasons;Q4=hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not;Q7=class hours missed due to health problems;Q8=class hours actually attended;Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity);Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent impairment while in class was calculated as: 100*Q9/10 and score ranged from 0-100% where higher numbers indicate greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions were: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending (0-10 scale, high scores = less productivity); Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent overall class impairment due to health problem calculated as: 100*{Q7/(Q7+Q8)+[(1- Q7/(Q7+Q8))×(Q9/10)]}, score range:0-100%, higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

WPAI+CIQ:10-item questionnaire used to assess degree to which AD affected work productivity and regular activities over past 7 days. Questions: Q1=currently employed; Q2=work hours missed due to health problems; Q3=work hours missed due to other reasons; Q4=hours actually worked; Q5=degree health affected productivity while working (0-10 scale, high scores =less productivity); Q6=classes attended in academic setting or not; Q7=class hours missed due to health problems; Q8=class hours actually attended; Q9=degree health affected productivity while attending(0-10 scale, high scores = less productivity);Q10=degree health affected productivity in regular daily activities(0-10 scale, high scores =less productivity). Percent activity impairment due to health problem calculated as: 100*Q10/10, scores ranged from 0-100%,higher numbers=greater impairment and less productivity.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-anxiety (HADS-A) and HADS-depression (HADS-D), each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety. HADS-A total score = sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. HADS-D assessed the state of lost interest and diminished pleasure response. HADS-D total score = sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

Eval-OL population included all participants that received at least 1 dose of study intervention in the OL period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure.

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A and HADS-D, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety. HADS-A total score = sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. HADS-D assessed the state of lost interest and diminished pleasure response. HADS-D total score = sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A and HADS-D, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety. HADS-A total score = sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. HADS-D assessed the state of lost interest and diminished pleasure response. HADS-D total score = sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A and HADS-D, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety. HADS-A total score = sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. HADS-D assessed the state of lost interest and diminished pleasure response. HADS-D total score = sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

Eval-DB population included all randomized participants with success in ISGA and EASI50 criteria as responders at randomization and received at least 1 dose of study intervention in the DB period. Here, ''Overall Number of Participants Analyzed'' signifies number of participants evaluable for this outcome measure and ''Number Analyzed'' signifies participants evaluable at specified time points.